John Carroll - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
John Carroll

John Carroll

Creator
0 followers

Veteran biotech journalist; founder of Endpoints News and known for insider industry insights.

Recent Posts

Finalizing Top 100 Biotech VCs, Join 2026 Webinar
Social•Feb 18, 2026

Finalizing Top 100 Biotech VCs, Join 2026 Webinar

We're wrapping up the fact checking process for our annual Top 100 biotech VCs list and prepping for our companion webinar on VC investing in 2026. If this is a topic near and dear to your heart, be sure to sign up. https://t.co/c16y04mFsD

By John Carroll
FDA's Erratic, Unpredictable Decisions Undermine Drug Regulation
Social•Feb 18, 2026

FDA's Erratic, Unpredictable Decisions Undermine Drug Regulation

The FDA keeps spinning, spinning, spinning round and round. Just what you want from a drug regulator: Erratic decision-making and complete unpredictability. https://t.co/q5abiPwgkW

By John Carroll
PET Scans Miss Cancer; System Needs Diagnostic Overhaul
Social•Feb 13, 2026

PET Scans Miss Cancer; System Needs Diagnostic Overhaul

Merkel cell carcinoma log, day #566. Completed my 6th PET scan at Dana-Farber yesterday. The radar, such as it is, doesn’t reflect any Merkel cell carcinoma. Lymph nodes look clean. The more I do PET scans, though, the more I...

By John Carroll
Sanofi's Board Ousts Hudson, New CEO Faces Dupixent Gap
Social•Feb 12, 2026

Sanofi's Board Ousts Hudson, New CEO Faces Dupixent Gap

So Sanofi's board strikes again. Paul Hudson gets the old Paris boot 6 years after taking on the task of remaking the pipeline. It hasn't gone well. Next: Belen Garijo. She has a few years to get ready for the...

By John Carroll
Biotech CEOs Dust Off S‑1s, Hopeful IPO Surge
Social•Jan 9, 2026

Biotech CEOs Dust Off S‑1s, Hopeful IPO Surge

That blowing sound you hear is from hundreds of biotech ceos blowing the dust off their S-1s, fingers crossed.

By John Carroll
Predicting $20B+ Biotech M&A Deal by 2026
Social•Jan 9, 2026

Predicting $20B+ Biotech M&A Deal by 2026

One of my #JPM26 predictions for 2026 is that we'll see a $20B-plus M&A deal in biotech. So here's hoping any RevMed deal comes after Monday morning. https://t.co/5pe4ymAILt

By John Carroll
Rampart's Fall Highlights Struggles in Legacy Gene Therapy
Social•Jan 8, 2026

Rampart's Fall Highlights Struggles in Legacy Gene Therapy

Ryan's story notes that it's hard to tell exactly what killed Rampart. The faltering gene therapy field, specific scientific challenges, (any internal conflict). Maybe all of the above? No matter what, though, another sign of the cold wind blowing through...

By John Carroll